Tolerogenic vaccines for the treatment of cardiovascular diseases

Atherosclerosis is the main pathology behind most cardiovascular diseases. It is a chronic inflammatory disease characterized by the formation of lipid-rich plaques in arteries. Atherosclerotic plaques are initiated by the deposition of cholesterol-rich LDL particles in the arterial walls leading to...

Full description

Saved in:
Bibliographic Details
Published inEBioMedicine Vol. 57; p. 102827
Main Authors Vigario, Fernando Lozano, Kuiper, Johan, Slütter, Bram
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.07.2020
Elsevier
Subjects
Atherosclerosis
Inflammation
Review
Tolerance
Vaccination
Tolerance
Inflammation
Vaccination
Atherosclerosis
Online AccessGet full text

Cover

More Information
Summary:Atherosclerosis is the main pathology behind most cardiovascular diseases. It is a chronic inflammatory disease characterized by the formation of lipid-rich plaques in arteries. Atherosclerotic plaques are initiated by the deposition of cholesterol-rich LDL particles in the arterial walls leading to the activation of innate and adaptive immune responses. Current treatments focus on the reduction of LDL blood levels using statins, however the critical components of inflammation and autoimmunity have been mostly ignored as therapeutic targets. The restoration of immune tolerance towards atherosclerosis-relevant antigens can arrest lesion development as shown in pre-clinical models. In this review, we evaluate the clinical development of similar strategies for the treatment of inflammatory and autoimmune diseases like rheumatoid arthritis, type 1 diabetes or multiple sclerosis and analyse the potential of tolerogenic vaccines for atherosclerosis and the challenges that need to be overcome to bring this therapy to patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2352-3964
2352-3964
DOI:10.1016/j.ebiom.2020.102827